Friday 6 November 2026 Export IONS’s income statement to Excel — free account

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.

Revenue: −40.7%
EPS: −188.5%
Free cash flow: +299.3%
Total debt: +116.0%

Quarter to June 2026, against a year earlier

Insider buying

39.48 0.68 +1.75%

Follow IONS

Alert me

Market cap: $6.5B
P/E: 0.0×
Fwd P/E: −12.2×
Dividend yield: —
F-score: 4/9
Altman Z: 2.12
Beneish M: −3.13
Dividend safety: n/a

Overview Business Profile Segments Valuation Filings

Ionis Pharmaceuticals, Inc. 8-K filed Jun 8, 2026

Period ended Jun 4, 2026 · Filed Jun 8, 2026 · accepted 12:49 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

Red flags

Officer departure Jun 8, 2026
Ionis Pharmaceuticals, Inc. reported the departure of an officer or director

8-K filed Jun 8, 2026 · The filing · sec.gov

Ionis Pharmaceuticals, Inc. 8-K filed Jun 8, 2026

Red flags

Stockrow Weekly